Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells
Open Access
- 1 July 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 30 (1) , 300-307
- https://doi.org/10.1002/hep.510300105
Abstract
Hepatitis B virus (HBV) is one of the major causes of chronic liver diseases and hepatocellular carcinoma. In this study, we used a single chain antibody (sFv), which is a man-made antibody with a strong affinity of immunoglobulin, to inhibit HBV replication. Because HBV replication can only take place in the viral nucleocapsid made of HBV core protein (HBc), we generated anti-HBc sFv and examined whether intracellular anti-HBc sFv could inhibit viral replication in the human hepatoblastoma-derived cell line that produces HBV (HB611). With respect to HBV replication intermediates, both single-stranded and partially double-stranded DNA intermediates were markedly suppressed in the cells expressing anti-HBc sFv, although HBV RNA intermediates were not affected. This suggested that intracellular anti-HBc sFv inhibited HBV DNA replication by inhibiting reverse transcription from HBV pregenome RNA to single-stranded DNA. Because the sFv-HBc complex was detected in the cells expressing anti-HBc sFv by immunoprecipitation analysis but the quantity of intracellular HBc was not affected, the anti-HBc sFv was suggested to inhibit HBV DNA replication by interfering with the function of HBc. These results indicate that intracellular sFv against HBc might be effective as a novel active molecule for gene therapy of hepatitis B.Keywords
This publication has 24 references indexed in Scilit:
- Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides, and dominant negative mutantsHepatology, 1997
- Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantationThe Lancet, 1997
- Lamivudine Is Effective in Suppressing Hepatitis B Virus Dna in Chinese Hepatitis B Surface Antigen Carriers: A Placebo–Controlled TrialHepatology, 1997
- The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trialsJournal of Hepatology, 1994
- Clinical aspects of hepatitis B virus infectionThe Lancet, 1993
- Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1993
- Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver DiseaseNew England Journal of Medicine, 1993
- Viral genetic variation: hepatitis B virus as a clinical exampleThe Lancet, 1993
- Inhibition of hepatitis B virus by antisense oligodeoxynucleotidesThe Lancet, 1991
- A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis BNew England Journal of Medicine, 1990